Idenix Pharmaceuticals Inc (IDIX) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
320 BENT STREET CAMBRIDGE, MA 02141 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 230,826 | |||
| Cash and cash equivalents | 230,826 | |||
| Restricted cash and investments | 2,103 | |||
| Receivables | 1,195 | |||
| Prepaid expense and other current assets | ✕ | 3,668 | ||
| Other current assets | ✕ | |||
| Total current assets: | 237,792 | |||
| Noncurrent Assets | ||||
| Property, plant and equipment | 3,274 | |||
| Long-term investments and receivables | 6,210 | |||
| Due from related parties | 6,210 | |||
| Other noncurrent assets | ✕ | |||
| Prepaid expense and other noncurrent assets | ✕ | 3,589 | ||
| Total noncurrent assets: | 13,073 | |||
| TOTAL ASSETS: | 250,865 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 18,010 | |||
| Employee-related liabilities | 2,946 | |||
| Accounts payable | 5,771 | |||
| Accrued liabilities | 9,293 | |||
| Other liabilities | 154 | |||
| Other undisclosed current liabilities | (2,232) | |||
| Total current liabilities: | 15,932 | |||
| Noncurrent Liabilities | ||||
| Liabilities, other than long-term debt | 11,785 | |||
| Deferred revenue and credits | 4,272 | |||
| Other liabilities | 7,513 | |||
| Other undisclosed noncurrent liabilities | 3,988 | |||
| Total noncurrent liabilities: | 15,773 | |||
| Total liabilities: | 31,705 | |||
| Equity | ||||
| Equity, attributable to parent | 219,160 | |||
| Common stock | 134 | |||
| Additional paid in capital | 926,671 | |||
| Accumulated other comprehensive income | 470 | |||
| Accumulated deficit | (708,115) | |||
| Total equity: | 219,160 | |||
| TOTAL LIABILITIES AND EQUITY: | 250,865 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|
| Revenues | 69,663 | ||
| Cost of revenue | (2,654) | ||
| Gross profit: | 67,009 | ||
| Operating expenses | (105,490) | ||
| Other undisclosed operating income | 3,100 | ||
| Operating loss: | (35,381) | ||
| Nonoperating income | 2,892 | ||
| Loss from continuing operations before income taxes: | (32,489) | ||
| Income tax benefit | 89 | ||
| Loss from continuing operations: | (32,400) | ||
| Loss before gain (loss) on sale of properties: | (32,400) | ||
| Net loss available to common stockholders, diluted: | (32,400) | ||
Comprehensive Income ($ in thousands)
| 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|
| Net loss: | (32,400) | ||
| Comprehensive loss: | (32,400) | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 105 | ||
| Comprehensive loss, net of tax, attributable to parent: | (32,295) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.